Evidence map›Paper›PMID 38963593›Full record

ReviewGastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association2024

Antibody-drug conjugates in gastric cancer: from molecular landscape to clinical strategies.

Jia-Lin Hao, Xin-Yun Li, Yu-Tong Liu, Ji-Xuan Lang, Di-Jie Liu, Chun-Dong Zhang

Abstract readReview
PubMed Publisher
In one paragraph

Review in Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Jia-Lin Hao *Central Laboratory, The Fourth Affiliated Hospital of China Medical University, Shenyang, 110032, China.
Xin-Yun Li *Clinical Medicine, The Fourth Affiliated Hospital of China Medical University, Shenyang, 110032, China.
Yu-Tong Liu *Department of Anesthesiology, Shengjing Hospital of China Medical University, Shenyang, 110022, China.
Ji-Xuan LangDepartment of Surgical Oncology, The Fourth Affiliated Hospital of China Medical University, Shenyang, 110032, China.
Di-Jie LiuCentral Laboratory, The Fourth Affiliated Hospital of China Medical University, Shenyang, 110032, China.
Chun-Dong ZhangCentral Laboratory, The Fourth Affiliated Hospital of China Medical University, Shenyang, 110032, China. cdzhang@cmu.edu.cn.ORCID 0000-0003-1804-1356

Funding

Scientific Study Project for Institutes of Higher Learning, Ministry of Education, Liaoning Province JYTMS20230108Young Backbone Talents of China Medical University RXXM202302
6 · The paper itself

Abstract

Antibody-drug conjugates (ADCs) represent a crucial component of targeted therapies in gastric cancer, potentially altering traditional treatment paradigms. Many ADCs have entered rigorous clinical trials based on biological theories and preclinical experiments. Modality trials have also been conducted in combination with monoclonal antibody therapies, chemotherapies, immunotherapies, and other treatments to enhance the efficacy of drug coordination effects. However, ADCs exhibit limitations in treating gastric cancer, including resistance triggered by their structure or other factors. Ongoing intensive researches and preclinical experiments are yielding improvements, while enhancements in drug development processes and concomitant diagnostics during the therapeutic period actively boost ADC efficacy. The optimal treatment strategy for gastric cancer patients is continually evolving. This review summarizes the clinical progress of ADCs in treating gastric cancer, analyzes the mechanisms of ADC combination therapies, discusses resistance patterns, and offers a promising outlook for future applications in ADC drug development and companion diagnostics.

Indexed as

ImmunoconjugatesStomach NeoplasmsAntineoplastic Agents, ImmunologicalDrug Resistance, NeoplasmHumansMolecular Targeted TherapyAntineoplastic Agents, ImmunologicalImmunoconjugatesAntibody–drug conjugatesCombination therapyCompanion diagnosticDrug resistanceGastric cancer

Identifiers

PMID38963593

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.